Covid Vaccines and ‘Emergency Use’ Authorization Explained.
David Dodd discussing COVID-19 Vaccines and 'Emergency Use' Authorization
https://youtu.be/Ppx8gQyYj8s?si=ACG31q97BSIBif4z&t=30
Ohio State University Completes Study on Pressure Bioscience (PBIO) and Protein Drinks.
Pressure BioSciences' Ultra Shear Technology Positioned for Critical Enabling Role in Global $41 Billion (2027) Plant Protein Beverage Market.
Revive’s Quarterly Report, Discussion, and a Video!
With 5,000 hospitalizations reported daily (150,000 a month), contracting Covid is not something to be taken lightly - after you get it....
Revive Therapeutics Gains 25% on Positive FDA Comments.
The Company stated yesterday that it "has received positive comments from the FDA in regard to the Company’s request to determine and...
Bavarian Nordic (BVNRY) Bags $119 Million Order from Joe Biden.
We Were up 80% on Bavarian For a Little While There. The Stock Looks Better Today, Then When we Originally Added...
Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?
Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found...
Cybin (CYBN) and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s...
- Preliminary data confirm Flow's ability to successfully measure neuro-effect of ketamine over 10 days -
- Results to...
Institutional Analyst Newsletter. April 14, 2022.
Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict
LIVE QUOTE
Report on Citius Pharma (CTXR): North Shore Research Issues a $10 Price Target, a...
We're Up 181% on Citius Pharma (CTXR), Despite its Being Well Below it's Recent High of $4.30. We Now Have Two $10...
Smart For Life to Present at The Noble Capital Markets Eighteenth Annual Investor Conference.
MIAMI, April 14, 2022 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a global leading...
Latest article
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...
